Moderna and Merck reported positive Phase 3 outcomes for their individualized mRNA neoantigen vaccine, intismeran autogene, alongside Keytruda in resected melanoma. In the INTerpath-001 trial (NCT05933577), the combination reduced the odds of recurrence or spread compared with Keytruda alone, with benefits reflected in both recurrence-free survival and distant metastasis-free survival endpoints. The readout helps validate the clinical utility of personalized cancer immunotherapy and feeds downstream interest in the enabling supply chain—particularly sequencing and companion workflow platforms used to build individualized vaccines. Investors highlighted potential tailwinds for sequencing providers tied to neoantigen identification.